Favipiravir shows improvement in moderate Covid-19 cases: Glenmark

The domestic pharma giant announced the launch of the first oral Favipiravir in the brand name "FabiFlu" claiming that it is backed by strong clinical evidence

Domestic pharmaceuticals manufacturer Glenmark on Saturday said that its antiviral drug -- Favipiravir -- had shown clinical improvement of up to 88 per cent in mild to moderate Covid-19 cases, including those with co-morbidities.

However, it said that pregnant and lactating mothers were not included in the clinical trial.

The domestic pharma giant announced the launch of the first oral Favipiravir in the brand name "FabiFlu" claiming that it was backed by strong clinical evidence showing encouraging results in patients with mild to moderate Covid-19.

"The antiviral offers broad-spectrum RNA virus coverage with clinical improvement noted across age groups 20